VA and Allelica Collaborate to Enhance Cardiovascular Disease Prevention Through Genomic Testing

VA and Allelica: A New Frontier in Cardiovascular Health

The U.S. Department of Veterans Affairs (VA) has embarked on a significant clinical study in partnership with Allelica, a pioneer in precision medicine. Their joint effort seeks to address one of the most pressing health challenges facing veterans—cardiovascular disease, which remains a leading cause of death among this population.

Understanding the Challenge

With more than 40% of veterans suffering from conditions such as hypertension and heart disease, there is an urgent need to mitigate the impacts of service-related risk factors which include exposure to environmental hazards, high rates of obesity, smoking, and mental health issues like post-traumatic stress disorder (PTSD).

Dr. Deepak Voora, a physician-scientist from Duke University and a cardiologist at the Durham VA Medical Center, is at the helm of this clinical trial. His goal is to explore how advanced therapeutic interventions can improve heart disease prevention strategies for veterans, specifically focusing on the role of clinical genomic testing in treatment.

The Study's Approach

The randomized clinical trial will involve veterans who are identified as being at risk for cardiovascular events but are not currently receiving cholesterol-lowering medications. Participants will be divided into two groups: one will receive standard care while the other will undergo a genomic risk assessment. This assessment employs polygenic risk scores (PRS) to gauge their likelihood of developing coronary artery disease (CAD) and pharmacogenetic testing of the SLCO1B1 gene to evaluate statin tolerance.

Allelica will play a critical role by providing this comprehensive genomic risk assessment. The company's innovative multi-ancestry PRS and SLCO1B1 pharmacogenetic testing will be made available to eligible veterans. This data will help healthcare providers tailor lipid-lowering therapies for better adherence, enhancing the effectiveness of the treatment while minimizing potential side effects.

Insights from Leadership

Giordano Botta, CEO of Allelica, expressed the importance of this collaboration by stating, "This project highlights the absolutely critical role of genomic testing in guiding interventions for the reduction of cardiovascular disease risk. We aim to proactively identify those at high risk of heart attack who are currently undetected by the standard care." The objective is clear: utilizing both PRS and pharmacogenetics can usher in a transformative preventive approach to cardiovascular care, allowing healthcare providers to act swiftly when there is still time to make a difference.

Implications for Future Healthcare

The implications of this study could extend well beyond its immediate participants. By demonstrating how personalized medicine can modify treatment protocols, the findings may influence how lipid-lowering drugs are prescribed throughout the VA healthcare system and potentially other healthcare frameworks, positively impacting millions at risk for cardiovascular disease.

About Allelica

Founded on precision medicine principles, Allelica specializes in leveraging multi-ancestry polygenic risk scores to predict genetic risks for various diseases. By integrating advanced bioinformatics, Allelica aims to empower healthcare reforms that can lead to reduced healthcare burdens associated with common diseases. With its technology supported by multiple patents and major scientific publications, Allelica is poised to make significant contributions to the health sector. For more information, visit allelica.com.

This collaboration between the VA and Allelica is a promising step toward revolutionizing the prevention and treatment of cardiovascular diseases in the veteran community, showcasing the vital role of genomics in modern medicine.